PUK16 - COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN PATIENTS WITH AUTOSOMAL POLYCYSTIC KIDNEY DISEASE- AN ADAPTATION OF THE ADPKD OUTCOMES MODEL
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2814
https://www.valueinhealthjournal.com/article/S1098-3015(18)36116-3/fulltext
Section Title :
Section Order :
2164
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)36116-3&doi=10.1016/j.jval.2018.09.2814